相关临床试验
123
14 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1920
进行中（未招募）
8
6.5%
已完成
73
59.4%
Enrolling By Invitation
1
0.8%
尚未招募
5
4.1%
招募中
16
13.0%
暂停
1
0.8%
Unknown
18
14.6%
撤回
1
0.8%
暂无批准数据
- A CAMH study provides the first direct evidence of dopamine neuron loss in long COVID, with PET scans showing significantly reduced dopamine transporter markers across all major striatal regions. - Lower dopamine markers correlated with specific symptoms: reduced motivation linked to ventral striatum, slower movement to dorsal putamen, and poorer memory to caudate putamen. - A separate Finnish study found no evidence of widespread neuroinflammation in long COVID patients compared to healthy controls, though increased cellular activity in the hippocampus and amygdala was tied to anxiety and depression severity. - CAMH researchers plan a clinical trial evaluating dopamine-targeting medications, potentially shifting treatment strategies from anti-inflammatory approaches toward restoring dopamine function.
- An international research team has solved molecular bottlenecks that have limited doxorubicin production since the 1970s, achieving 180% higher yields than current industrial methods. - The breakthrough involved identifying three key constraints: the biological power supply mechanism, a protective protein system, and unfavorable enzyme positioning that slowed natural production. - The advancement could significantly reduce manufacturing costs and improve accessibility for this cornerstone cancer therapy that treats over one million patients annually worldwide. - Researchers established Meta-Cells Oy as a spin-out company to commercialize the technology and develop sustainable biosynthetic production methods for essential cancer drugs.
- Faron-supported research published in Theranostics identified secreted Clever-1 (sClever-1) as a key immunosuppressive mediator that impairs T-cell responses and contributes to anti-PD-1 therapy resistance in cancer patients. - The study analyzed plasma samples from 139 breast cancer patients and 193 bexmarilimab-treated participants, demonstrating that sClever-1 levels were significantly elevated in cancer patients compared to healthy individuals. - Bexmarilimab treatment significantly reduced circulating sClever-1 levels in patients, correlating with decreased T-cell engagement and providing mechanistic validation for the drug's immune-activating properties. - High sClever-1 levels were associated with resistance to anti-PD-1 checkpoint inhibitors, suggesting potential utility as a biomarker for guiding immunotherapy treatment strategies.
- University of Turku scientists have identified a five-gene signature that predicts which cancer patients will respond to bexmarilimab immunotherapy, potentially improving treatment outcomes through personalized selection. - The study revealed bexmarilimab works best in "immunologically silent" tumor environments by activating macrophages against cancer cells, while also triggering B cell responses in adjacent healthy tissue. - This Finnish-developed immunotherapy has shown promising results across multiple solid tumor types, with researchers now working toward clinical validation of the gene signature for patient profiling.
